Skip to main content
. 2021 May 10;21:212. doi: 10.1186/s12876-021-01782-w

Fig. 4.

Fig. 4

Prevalence of MS, dyslipidaemia and hyperuricaemia in individuals with and without MAFLD. The prevalence of MS, dyslipidaemia and hyperuricaemia and its CIs in individuals (total population, males and females) with and without MAFLD were calculated